Malignant Gliomas account for over 60% of all primary brain tumors, of which malignant astrocytomas represent the most common histologic classification. Among the astrocytomas, there appear to be a continuum in malignant progression from low-grade astrocytoma to anaplastic astrocytoma to glioblastoma multiforme. While the clinical-pathological relationship among various types of astrocytomas is obvious, the specific molecular and cellular events leading to tumorigenesis and tumor progression are far from clear. This proposal is designed to examine the possible role of transforming growth factor alpha (TGF-alpha) and its interaction with epidermal growth factor receptor in tumorigenesis and progression of human gliomas. With the aid of our previous investigations demonstrating amplification of EGF receptor gene in untreated highly malignant glioblastoma, and amplification and rearrangement of TGF-alpha gene in recurrent astrocytomas, our efforts will be directed at examining the expression and activities of TGF-alpha, EGF and EGF-R receptor in fresh and cultured human glioma cells. Particular emphasis will be placed on identifying and characterizing alterations in TGF-alpha gene and protein products in recurrent gliomas. The role of TGF gene in tumorigenesis will be examined by transfection studies in normal glial cells with TGF-alpha gene, or altered TGF-alpha and EGF-receptor genes as identified during the course of this proposal. Molecular cloning of altered TGF-alpha and EGF- receptor genes will be performed to establish the biological significance of the potential altered protein products. An understanding of the purported autocrine growth regulatory mechanism involving TGF-alpha and EGF-R and the molecular control of tumor progression in human gliomas may allow us to discover new targets for specific therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA051148-03
Application #
3195852
Study Section
Pathology A Study Section (PTHA)
Project Start
1989-12-01
Project End
1994-11-30
Budget Start
1991-12-03
Budget End
1992-11-30
Support Year
3
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
Other Domestic Higher Education
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Cerrato, Julie A; Khan, Tahira; Koul, Dimpy et al. (2004) Differential activation of the Fas/CD95 pathway by Ad-p53 in human gliomas. Int J Oncol 24:409-17
Ke, Li Dao; Shi, Yue-Xi; Yung, W K Alfred (2002) VEGF(121), VEGF(165) overexpression enhances tumorigenicity in U251 MG but not in NG-1 glioma cells. Cancer Res 62:1854-61
Koul, Dimpy; Jasser, Samar A; Lu, Yiling et al. (2002) Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. Oncogene 21:2357-64
Koul, D; Parthasarathy, R; Shen, R et al. (2001) Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN. Oncogene 20:6669-78
Cerrato, J A; Yung, W K; Liu, T J (2001) Introduction of mutant p53 into a wild-type p53-expressing glioma cell line confers sensitivity to Ad-p53-induced apoptosis. Neuro Oncol 3:113-22
Ke, L D; Shi, Y X; Im, S A et al. (2000) The relevance of cell proliferation, vascular endothelial growth factor, and basic fibroblast growth factor production to angiogenesis and tumorigenicity in human glioma cell lines. Clin Cancer Res 6:2562-72
Glass, T L; Liu, T J; Yung, W K (2000) Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336. Neuro Oncol 2:151-8
Ke, L D; Chen, Z; Yung, W K (2000) A reliability test of standard-based quantitative PCR: exogenous vs endogenous standards. Mol Cell Probes 14:127-35
Tang, P; Jasser, S A; Sung, J C et al. (1999) Transforming growth factor-alpha antisense vectors can inhibit glioma cell growth. J Neurooncol 43:127-35
Sano, T; Lin, H; Chen, X et al. (1999) Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res 59:1820-4

Showing the most recent 10 out of 20 publications